18392493. LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF simplified abstract (PURDUE RESEARCH FOUNDATION)
Contents
- 1 LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF
Organization Name
Inventor(s)
Philip Stewart Low of West Lafayette IN (US)
Jyoti Roy of West Lafayette IN (US)
LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 18392493 titled 'LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF
Simplified Explanation
The present teachings involve conjugates and methods for imaging a tumor microenvironment and treating LHRH-R expressing cancer in a patient, as well as methods of making conjugates with an LHRH-R antagonist.
- Conjugates and methods for imaging a tumor microenvironment in a patient
- Conjugates and methods for treating LHRH-R expressing cancer in a patient
- Method of making conjugates comprising an LHRH-R antagonist
Potential Applications
This technology could be applied in the fields of oncology, radiology, and drug development.
Problems Solved
This technology helps in accurately imaging tumor microenvironments and treating LHRH-R expressing cancer, leading to more targeted and effective therapies.
Benefits
The benefits of this technology include improved diagnosis and treatment of cancer, potentially leading to better patient outcomes and reduced side effects.
Potential Commercial Applications
Potential commercial applications of this technology could include the development of new imaging agents and targeted cancer therapies.
Possible Prior Art
Prior art may include existing methods for imaging tumor microenvironments and treating LHRH-R expressing cancer, as well as known LHRH-R antagonists.
Unanswered Questions
How does this technology compare to existing imaging methods for tumor microenvironments?
This article does not provide a direct comparison to existing imaging methods for tumor microenvironments. Further research or clinical trials may be needed to determine the superiority of this technology.
What are the potential side effects of using LHRH-R antagonists in cancer treatment?
The article does not address the potential side effects of using LHRH-R antagonists in cancer treatment. Additional studies or trials may be required to assess the safety profile of this approach.
Original Abstract Submitted
The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.
